Fisher Asset Management LLC Boosts Holdings in Zimmer Biomet Holdings, Inc. (NYSE:ZBH)

Fisher Asset Management LLC lifted its stake in Zimmer Biomet Holdings, Inc. (NYSE:ZBH) by 7.1% in the 4th quarter, Holdings Channel.com reports. The firm owned 5,248 shares of the medical equipment provider’s stock after buying an additional 348 shares during the quarter. Fisher Asset Management LLC’s holdings in Zimmer Biomet were worth $554,000 as of its most recent SEC filing.

Other large investors have also recently modified their holdings of the company. Stonebridge Financial Group LLC purchased a new position in shares of Zimmer Biomet in the 4th quarter worth about $25,000. Dunhill Financial LLC raised its position in Zimmer Biomet by 1,090.0% in the 3rd quarter. Dunhill Financial LLC now owns 238 shares of the medical equipment provider’s stock worth $26,000 after buying an additional 218 shares during the last quarter. Ashton Thomas Securities LLC purchased a new position in Zimmer Biomet in the 3rd quarter worth about $28,000. Brooklyn Investment Group purchased a new position in Zimmer Biomet in the 3rd quarter worth about $35,000. Finally, Kentucky Trust Co purchased a new position in Zimmer Biomet in the 4th quarter worth about $39,000. Hedge funds and other institutional investors own 88.89% of the company’s stock.

Zimmer Biomet Trading Up 0.5 %

Shares of NYSE:ZBH opened at $105.27 on Friday. The stock has a 50 day moving average of $105.53 and a 200 day moving average of $107.25. The company has a market cap of $20.96 billion, a PE ratio of 23.66, a price-to-earnings-growth ratio of 1.95 and a beta of 1.02. The company has a current ratio of 1.91, a quick ratio of 0.99 and a debt-to-equity ratio of 0.43. Zimmer Biomet Holdings, Inc. has a 12-month low of $97.69 and a 12-month high of $133.90.

Zimmer Biomet (NYSE:ZBH) last posted its quarterly earnings results on Thursday, February 6th. The medical equipment provider reported $2.31 earnings per share for the quarter, topping the consensus estimate of $2.30 by $0.01. Zimmer Biomet had a return on equity of 12.99% and a net margin of 11.77%. During the same period in the prior year, the business posted $2.20 earnings per share. As a group, equities research analysts expect that Zimmer Biomet Holdings, Inc. will post 8.22 EPS for the current year.

Zimmer Biomet Dividend Announcement

The firm also recently declared a quarterly dividend, which will be paid on Wednesday, April 30th. Shareholders of record on Monday, March 31st will be paid a $0.24 dividend. The ex-dividend date is Monday, March 31st. This represents a $0.96 annualized dividend and a yield of 0.91%. Zimmer Biomet’s payout ratio is 21.57%.

Wall Street Analyst Weigh In

A number of equities analysts have weighed in on ZBH shares. JMP Securities reissued a “market outperform” rating and issued a $140.00 target price on shares of Zimmer Biomet in a research report on Friday, February 7th. Royal Bank of Canada decreased their target price on Zimmer Biomet from $130.00 to $125.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. Raymond James decreased their target price on Zimmer Biomet from $126.00 to $119.00 and set an “outperform” rating for the company in a research report on Friday, February 7th. JPMorgan Chase & Co. raised Zimmer Biomet from a “neutral” rating to an “overweight” rating and boosted their target price for the stock from $125.00 to $128.00 in a research report on Tuesday, December 17th. Finally, Truist Financial reaffirmed a “hold” rating and set a $113.00 price target (down previously from $118.00) on shares of Zimmer Biomet in a research report on Monday, February 10th. Two analysts have rated the stock with a sell rating, eleven have given a hold rating and nine have assigned a buy rating to the stock. Based on data from MarketBeat, the stock currently has an average rating of “Hold” and a consensus price target of $124.15.

Zimmer Biomet Company Profile

Zimmer Biomet Holdings, Inc, together with its subsidiaries, operates as a medical technology company worldwide. The company designs, manufactures, and markets orthopedic reconstructive products, such as knee and hip products; S.E.T. products, including sports medicine, biologics, foot and ankle, extremities, and trauma products; craniomaxillofacial and thoracic products comprising face and skull reconstruction products, as well as products that fixate and stabilize the bones of the chest to facilitate healing or reconstruction after open heart surgery, trauma, or for deformities of the chest.